ArticleCancer immunology, immunotherapy : CII2017
Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 76 citations in OpenAlex.
- Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.International immunopharmacology · 2018Trial
- Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study.Annals of medicine · 2026Observational
- Dynamics changes of spleen volume predict survival outcomes in unresectable hepatocellular carcinoma treated with tislelizumab plus lenvatinib.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Targeting ABL kinases overcomes melanoma immune evasion following resistance to MAPK inhibition.Nature communications · 2026Article
- Human immunosuppressive neutrophils: recent answers to old and new questions.The EMBO journal · 2026Review
- Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer.Molecular cancer · 2026Article
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Article
- Immune-imaging biomarkers: Prognostic value of splenic volume and circulating lymphocytes in upper tract urothelial carcinoma.Oncology letters · 2026Article
- An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.The oncologist · 2026Article
- The Prognostic Value of Biomarkers Identified by [Diagnostics (Basel, Switzerland) · 2025Article
- Tumor microenvironment remodeling with a telomere-targeting agent and its cooperative antitumor effects with a nanovaccine.Journal of nanobiotechnology · 2025Article
- Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors.Scientific reports · 2025Article
- Ferroptosis contributes to immunosuppression.Frontiers of medicine · 2025Review
- Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study.American journal of cancer research · 2025Article
- Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.Nature nanotechnology · 2024Article
- The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.Journal of experimental & clinical cancer research : CR · 2024Review
- Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis.Science immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of myeloid cells that are increased in the peripheral blood of cancer patients and limit productive immune responses against tumors. Immunosuppressive MDSCs are well characterized in murine splenic tissue and are found at higher frequencies in spleens of tumor-bearing mice. However, no studies have yet analyzed these cells in parallel human spleens. We hypothesized that MDSCs would be increased in the spleens of human cancer patients, similar to tumor-bearing mice. We compared the frequency and function of MDSC subsets in dissociated human spleen from 16 patients with benign pancreatic cysts and 26 patients with a variety of cancers. We found that total MDSCs (Lin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.